Table 1.

CI analysis of TH-302 combined with bortezomib at a nonconstant ratio in 5T33vt cells

TH-302 (μmol/L)Bortezomib (nmol/L)FaCIDescription
2.550.3820.638Synergism
2.5100.5560.569Synergism
2.5200.6050.891Slight synergism
550.5350.452Synergism
5100.6030.550Synergism
5200.8280.370Synergism
1050.5760.538Synergism
10100.7770.308Synergism
10200.8260.404Synergism

NOTE: Analysis was conducted using the CompuSyn software (ComboSyn, Inc.). Descriptions are based on CI values and the recommendations of CompuSyn: <0.1, very strong synergism; 0.1–0.3, strong synergism; 0.3–0.7, synergism; 0.7–0.85, moderate synergism; 0.85–0.9, slight synergism.

Abbreviation: Fa, fraction affected as tested by the flow cytometry analysis of 5T33vt cells stained with FITC-labeled Annexin V and 7-AAD after 16 hours with each indicted treatment.